HCC 19-059 - ICONIC Study
Do you have a rare genitourinary (GU) tumor? If so, you may be eligible to participate in a study to help researchers test the good and bad effects of three combined cancer drugs, called cabozantinib, nivolumab, and ipilimumab, that are FDA-approved individually, but not in combination.